Alligator Bioscience appoints Søren Bregenholt as new CEO
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Board of Directors has appointed Søren Bregenholt, Ph.D. as the company’s new Chief Executive Officer (CEO), to strengthen Alligator’s business development activities and clinical progress on an international level. Dr. Søren Bregenholt will take up the position on 1 June 2021, succeeding Per Norlén, who will remain in the company. In order to facilitate the transition, Malin Carlsson, Alligator’s COO, is appointed as interim CEO.
Press inquiries should be adressed to: